Biofrontera's earnings call reflects a successful first half of 2025 marked by record sales, strategic independence, and strong financial backing, despite increased net losses and legal costs. The overall sentiment is buoyed by positive operational changes and future growth prospects.

Company Guidance

In the recent Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call, the company reported a record-breaking performance for the first half of the year, driven by strategic changes in customer segmentation and sales approach. They sold over 50,000 tubes of Ameluz in the first half of the year and placed 40 RhodoLED XL lamps in physician offices, contributing to growth prospects. The restructuring of their relationship with Biofrontera AG led to a new royalty model, reducing costs significantly. Total revenues for Q2 2025 increased to $9.0 million, up from $7.8 million in Q2 2024, driven by a 5% higher unit sale price and a 9.5% increase in sales volume. Despite a net loss of $5.3 million for the quarter, the company achieved an adjusted EBITDA of negative $5.1 million, reflecting improved cost management. Future growth is expected from expanding indications for Ameluz, including the potential treatment of acne vulgaris and superficial basal cell carcinoma. The company also highlighted a strategic $11 million investment that facilitated their operational transformation.

Record-Breaking Sales of Ameluz

For the first time, Biofrontera sold over 50,000 tubes of Ameluz in the first half of 2025, showcasing a successful strategic shift and customer segmentation.

Increased Lamp Installations

40 RhodoLED XL lamps were placed in physician offices during the first half of 2025, signaling strong future growth with over 700 lamps now in use.

Total Revenue Growth

Total revenues for the second quarter of 2025 were $9.0 million, a 15.4% increase from $7.8 million in the second quarter of 2024.

Improved Gross Margins

Cost of revenues decreased by 42% compared to the same period in 2024, due to a shift to a royalty model and improved operational efficiencies.

Successful Restructuring with Biofrontera AG

Biofrontera Inc. became independent from Biofrontera AG, with a new agreement reducing the Ameluz transfer price and improving financial terms.

Strong Financial Support

Biofrontera secured an $11 million investment to support restructuring efforts and future growth.

Pipeline Progress

Completed enrollment in the Phase III study for actinic keratosis on the trunk, neck, and extremities, and Phase III trial for superficial basal cell carcinoma, with a promising outlook for FDA submissions.

Patent Extension

Received patent approval extending Ameluz's protection through December 2043, supporting long-term investment recovery and profitability.

Biofrontera (BFRI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BFRI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 30, 2025	2025 (Q3)	-0.41 / -	-0.98	―	―	―
Aug 13, 2025	2025 (Q2)	-0.42 / -0.57	-0.05	-1040.00% (-0.52)	―
May 15, 2025	2025 (Q1)	-0.21 / -0.47	-2.88	83.68% (+2.41)	―
Mar 21, 2025	2024 (Q4)	-0.03 / -0.19	4.45	-104.27% (-4.64)	―
Nov 13, 2024	2024 (Q3)	-0.83 / -0.98	-4.64	78.88% (+3.66)	―
Aug 14, 2024	2024 (Q2)	-0.77 / -0.05	-7.23	99.31% (+7.18)	―
May 15, 2024	2024 (Q1)	-1.17 / -2.88	-5.6	48.57% (+2.72)	―
Mar 15, 2024	2023 (Q4)	-1.19 / 4.45	-2.1	311.90% (+6.55)	―
Nov 09, 2023	2023 (Q3)	-3.79 / -4.64	-2.2	-110.91% (-2.44)	―
Aug 11, 2023	2023 (Q2)	-43.37 / -7.23	-1	-623.00% (-6.23)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BFRI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.95	$0.97	+2.11%
May 15, 2025	$0.70	$0.65	-7.14%
Mar 21, 2025	$1.03	$0.86	-16.50%
Nov 13, 2024	$0.83	$0.70	-15.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Biofrontera (BFRI) report earnings?

Biofrontera (BFRI) is schdueled to report earning on Nov 30, 2025, Before Open (Confirmed).

What is Biofrontera (BFRI) earnings time?

Biofrontera (BFRI) earnings time is at Nov 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BFRI EPS forecast?

BFRI EPS forecast for the fiscal quarter 2025 (Q3) is -0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing